Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
曲妥珠单抗德鲁替康治疗HER2低表达转移性乳腺癌:随机3期DESTINY-Breast04试验的长期生存分析
期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-025-03981-4
Modi, Shanu; Jacot, William; Iwata, Hiroji; Park, Yeon Hee; Vidal Losada, Maria; Li, Wei; Tsurutani, Junji; Ueno, Naoto T; Zaman, Khalil; Prat, Aleix; Papazisis, Konstantinos; Rugo, Hope S; Yamashita, Toshinari; Harbeck, Nadia; Im, Seock-Ah; De Laurentiis, Michelino; Pierga, Jean-Yves; Wang, Xiaojia; Gombos, Andrea; Tokunaga, Eriko; Orbegoso Aguilar, Cecilia; Yung, Lotus; Xiao, Feng; Cheng, Yingkai; Cameron, David